First Boston Pharma acquires NutraMax Products
GLOUCESTER, Mass. First Boston Pharma on Wednesday announced its acquisition of NutraMax Products, a contract manufacturer of solid dose and soft chew pharmaceuticals and supplements.
The company will now be known as First Boston Pharma. Leading the First Boston Pharma organization will be Mario Medri, the company stated.
“The acquisition by [Medri] and the First Boston Pharma Group will propel the company further and faster along the trajectory we are on, particularly with designer products for pharmaceuticals and supplement markets,” stated Rodney Plunkett, First Boston Pharma EVP. “To have the industry’s foremost innovator leading First Boston Pharma into the future is an exciting prospect for us and for our customers.”
The acquisition of NutraMax by First Boston Pharma will provide the necessary resources for the company to pursue its strategy of innovation in the over-the-counter drugs and supplements categories.
“One of our key strategies is to move to a supply base integrity model, which gives our customers the differentiated products they need, when they want them,” Medri said.
NutraMax Products should not be confused with the Maryland-based company with a similar name — Nutramax Laboratories — which distributes a number of supplement products, including the glucosamine/chondroitin product Cosamin DS.
Colmers seeks feedback from UMD School of Pharmacy about H1N1 virus
BALTIMORE, Md. Concerning the current outbreak of H1N1, or swine flu, Maryland’s top health official asked for feedback from the University of Maryland School of Pharmacy, with its network of pharmacists, on “what worked and what didn’t work,” the pharmacy school announced Monday.
John Colmers, Maryland secretary of health and mental hygiene, said during a recent meeting of the School of Pharmacy Board of Visitors that “we are not out of the woods yet. We have identified that this is a virus that is in our population, and we are in the phase now of lessons learned.”
He said his department is gathering data on medication and counseling provided by pharmacists during the outbreak. Colmers said the availability of antiviral drugs was of great interest during the swine flu outbreak.
Although the federal government released 25% of its stockpile of medications and supplies for a possible pandemic, Colmers said, “We don’t understand the supply side.” He said a policy is needed to obtain better information on what is available during an outbreak.
Mayer Labs to relaunch the Today Sponge
BERKELEY, Calif. Mayer Labs on Tuesday announced that it will relaunch the Today Sponge, possibly marking the fourth time the over-the-counter birth control product has been introduced to the U.S. market.
According to Mayer, the product already has distribution through CVS, Walgreens and Duane Reade, three retailers who had carried the product before.
Today Sponge was originally introduced in 1983 and removed from the market due to manufacturing problems in 1994, according to published reports. The product was reintroduced into U.S. stores in 2005 by Allendale Pharmaceuticals, which was acquired by Synova Healthcare Group in 2007. Synova “re-launched” the Today Sponge soon after it acquired Allendale, but filed for bankruptcy protection later that year. Now Mayer has acquired the manufacturing and distribution rights to the birth control product.
“We are very pleased to add the Today Sponge to our portfolio of high quality reproductive products,” stated David Mayer, CEO of Mayer Labs. “The recent interruption of distribution was not the result of product quality or consumer demand, but was due to the previous owner, Synova Healthcare Group, filing bankruptcy.”
The Today Sponge is being relaunched with new packaging and Web site. Suggested retail price for a 3-pack is $14.99.